Alembic Pharmaceuticals gets USFDA approval for Clomipramine Hydrochloride Capsules

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, the company said in a statement.

It also said that the approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product, Anafranil Capsules, 25 mg, 50 mg and 75 mg, of SpecGX LLC. Clomipramine Hydrochloride Capsules are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD).

Clomipramine Hydrochloride Capsules USP, 25 mg, 50 mg and 75 mg, have an estimated market size of $32 million for twelve months ending June 2021, according to IQVIA, the statement added.

“Alembic has a cumulative total of 149 ANDA approvals (131 final approvals and 18 tentative approvals) from FDA,” it further mentioned.